2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh risk
2019
Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series
Gnanapandithan K, Kharel P, Grimshaw A, Giri S. Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series. Blood 2019, 134: 3606. DOI: 10.1182/blood-2019-132203.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAutoimmune hemolytic anemiaPure red cell aplasiaImmune thrombocytopeniaThrombotic thrombocytopenic purpuraCase reportICI therapyIntravenous immunoglobulinHematopoietic growth factorsCheckpoint inhibitorsMost patientsAdverse eventsHemophagocytic lymphohistiocytosisSupportive treatmentCase seriesClinical presentationCommon subtypeTreatment strategiesEligibility criteriaSystematic reviewNon-small cell lung cancerOrgan systemsGrowth factorAnti-thymocyte globulinHigh-dose corticosteroids